Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength

Neuronetics

11/08/2026 13:02

Overview
US interventional mental health firm's Q2 revenue rose 9%, beating analyst expectations
Adjusted EBITDA turned positive, net loss narrowed from prior year
Company strengthened leadership team with new CFO and other executive appointments

Outlook
Neuronetics sees 2026 revenue between $160 mln and $164 mln, down from prior $160 mln-$166 mln
Company expects 2026 gross margin between 48% and 50%, up from prior 47%-49%
Neuronetics projects 2026 operating expenses of $95 mln-$100 mln, down from prior $100 mln-$105 mln

Result Drivers
GREENBROOK GROWTH - Co said higher Greenbrook clinic revenue drove overall revenue increase
GROSS MARGIN IMPROVEMENT - Co attributed higher gross margin to new go-to-market strategy and improved revenue cycle management at Greenbrook clinics
LOWER OPERATING EXPENSES - Co said decrease in operating expenses was mainly due to lower general and administrative and sales and marketing costs

Company press release: ID:nGNXcg21Xj

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$41.57 mln
$40.18 mln (4 Analysts)
Q2 Loss Per Share
 
$0.05
 
Q2 Gross Margin
 
51.10%
 
Q2 Operating Expenses
 
$22.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Neuronetics Inc is $4.00, about 84.3% above its August 10 closing price of $2.17

Reuters Recommended Reads
Aug 10 - Axsome Therapeutics Q2 revenue rises on AUVELITY  growth
Aug 10 - Tactile Systems Q2 revenue up 9%, slightly beats estimates
Aug 11 - Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)